Dimensional Fund Advisors
PACB icon

Dimensional Fund Advisors’s Pacific Biosciences PACB Stock Holding History

Dimensional Fund Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28M Sell
759,783
-139,767
-16% -$203K ﹤0.01% 2821
2026
Q1 		$1.19M Buy
899,550
+575,801
+178% +$1.03M ﹤0.01% 2812
2025
Q4 		$603K Sell
323,749
-39,074
-11% -$75.1K ﹤0.01% 2940
2025
Q3 		$464K Sell
362,823
-27,760
-7% -$37.6K ﹤0.01% 3006
2025
Q2 		$485K Sell
390,583
-56,405
-13% -$65.1K ﹤0.01% 2999
2025
Q1 		$527K Sell
446,988
-49,828
-10% -$76.4K ﹤0.01% 2999
2024
Q4 		$909K Sell
496,816
-53,059
-10% -$104K ﹤0.01% 2933
2024
Q3 		$935K Sell
549,875
-763,262
-58% -$1.25M ﹤0.01% 2923
2024
Q2 		$1.8M Sell
1,313,137
-2,121,331
-62% -$4.28M ﹤0.01% 2786
2024
Q1 		$12.9M Buy
3,434,468
+377,206
+12% +$2.21M ﹤0.01% 2199
2023
Q4 		$30M Sell
3,057,262
-98,944
-3% -$809K 0.01% 1770
2023
Q3 		$26.4M Sell
3,156,206
-405,836
-11% -$4.64M 0.01% 1771
2023
Q2 		$47.4M Sell
3,562,042
-23,331
-0.7% -$284K 0.02% 1393
2023
Q1 		$41.5M Buy
+3,585,373
New +$35.6M 0.01% 1465
2022
Q3 		$1.05M Buy
+180,435
New +$1.04M ﹤0.01% 2868
2022
Q1 		– Sell
-65,657
Closed -$1.34M – 3547
2021
Q4 		$1.34M Buy
65,657
+310
+0.5% +$7.48K ﹤0.01% 2952
2021
Q3 		$1.67M Buy
65,347
+13,166
+25% +$390K ﹤0.01% 2903
2021
Q2 		$1.82M Sell
52,181
-70,991
-58% -$2.06M ﹤0.01% 2891
2021
Q1 		$4.12M Buy
+123,172
New +$4.31M ﹤0.01% 2639
2015
Q2 		– Sell
-335,413
Closed -$1.96M – 3368
2015
Q1 		$1.96M Sell
335,413
-161,105
-32% -$1.11M ﹤0.01% 2837
2014
Q4 		$3.89M Sell
496,518
-100,983
-17% -$646K ﹤0.01% 2651
2014
Q3 		$2.93M Sell
597,501
-171,287
-22% -$896K ﹤0.01% 2727
2014
Q2 		$4.75M Sell
768,788
-40,835
-5% -$204K ﹤0.01% 2586
2014
Q1 		$4.33M Sell
809,623
-18,011
-2% -$114K ﹤0.01% 2606
2013
Q4 		$4.33M Buy
827,634
+143,828
+21% +$660K ﹤0.01% 2621
2013
Q3 		$3.78M Buy
683,806
+212,184
+45% +$737K ﹤0.01% 2656
2013
Q2 		$1.19M Buy
+471,622
New +$1.17M ﹤0.01% 2974

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors's PACB Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its Pacific Biosciences (PACB) stake by 16% in Q2 2026, selling an estimated $203K and leaving 759,783 shares worth $1.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2821.

Dimensional Fund Advisors first reported a position in PACB in Q2 2013 and has held it in 27 quarters since. The position peaked at $47.4M in Q2 2023. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Dimensional Fund Advisors held 759,783 shares of Pacific Biosciences worth $1.28M as of Q2 2026.
  • Dimensional Fund Advisors sold 139,767 Pacific Biosciences shares in Q2 2026, an estimated $203K.
  • Pacific Biosciences made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2821 holding.
  • Dimensional Fund Advisors first reported a position in Pacific Biosciences in Q2 2013 and has held it in 27 quarters since.
  • Dimensional Fund Advisors's Pacific Biosciences position peaked at $47.4M in Q2 2023.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.